Home Cart Sign in  
Chemical Structure| 2828433-17-4 Chemical Structure| 2828433-17-4

Structure of 2828433-17-4

Chemical Structure| 2828433-17-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LSKL is a peptide derived from LAP-TGFβ that competitively inhibits TGF-β1 activity, alleviating liver fibrosis and renal interstitial fibrosis, and can cross the blood-brain barrier to inhibit subarachnoid fibrosis, preventing chronic hydrocephalus and improving neurocognitive deficits after subarachnoid hemorrhage, suitable for research on various fibrotic diseases.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA)

CAS No. :2828433-17-4
Formula : C23H43F3N6O7
M.W : 572.62
SMILES Code : O=C(N[C@@H](CC(C)C)C(N)=O)[C@@H](NC([C@@H](NC([C@@H](N)CC(C)C)=O)CO)=O)CCCCN.O=C(O)C(F)(F)F
MDL No. :N/A

Safety of LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA)

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
mouse podocytes 5 μM 24 hours inhibiting TSP-1 to protect against HG-induced podocyte injury Cell Death Dis. 2022 Jul 30;13(7):663
human trabecular meshwork (hTM) cells 5 µM 2 days LSKL inhibited TSP1 gene and protein expression and reduced hTM cell migration J Cell Physiol. 2021 Dec;236(12):8226-8238

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice 70% hepatectomy model Intraperitoneal injection 30mg/kg bodyweight Two doses (at abdominal closure and 6h post-surgery) To evaluate the effect of LSKL peptide on liver regeneration after hepatectomy. Results showed that LSKL peptide significantly inhibited Smad2 phosphorylation, accelerated S-phase entry of hepatocytes, promoted liver regeneration and bodyweight recovery, with no significant adverse effects observed. Br J Surg. 2015 Jun;102(7):813-25
C57BL/6J mice Senecionine-induced hepatic sinusoidal obstruction syndrome (HSOS) model Intraperitoneal injection 30 mg/kg Two doses, at 0.25 and 6 hours after senecionine treatment To evaluate the protective effect of LSKL against senecionine-induced HSOS. Results showed that LSKL significantly reduced serum ALT and AST activities, alleviated liver tissue damage, and decreased the expression of TSP1 and MMP9. Arch Toxicol. 2022 Jul;96(7):2003-2019
Rats Febrile seizure model Intracerebroventricular injection 20μg/μl Once daily Inhibition of the TSP-1/TGF-β1 pathway reduces excitatory synapse formation and decreases epileptic susceptibility Cell Death Discov. 2024 Feb 12;10(1):73
SCID mice SCID-tibia model Osmotic pump 30 mg/kg/day For 4 weeks LSKL significantly reduced tumor burden and TGF-β signaling in the bone marrow. Am J Pathol. 2016 Mar;186(3):678-90
C57BL/6J mice Ex vivo mouse eyes Perfusion 50 µM Continuous perfusion LSKL increased outflow facility in ex vivo mouse eyes, similar to the effect of Y39983 J Cell Physiol. 2021 Dec;236(12):8226-8238

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.75mL

0.35mL

0.17mL

8.73mL

1.75mL

0.87mL

17.46mL

3.49mL

1.75mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
 

Historical Records

Categories